Parkinson's disease represents a growing neurological health burden in India. In light of recent scientific advances in brain network mapping, examine the limitations of existing t

GS2 Healthcare
Parkinson's disease represents a growing neurological health burden in India. In light of recent scientific advances in brain network mapping, examine the limitations of existing treatments and the potential of non-invasive therapies like Transcranial Magnetic Stimulation (TMS) for improving patient outcomes.

Examine

  • 15 marks
  • 8 min
  • 250 words
  • Hard

The Hindu

Read article →

Introduction

Parkinson’s disease (PD), affecting millions globally, is an increasing neurological burden in India. Recent advances in brain network mapping offer new avenues for targeted, non-invasive therapies such as Transcranial Magnetic Stimulation (TMS).

Limitations of Existing Treatments

  • Symptomatic focus: Drugs like Levodopa address symptoms but do not halt disease progression.
  • Diminishing efficacy: Long-term use leads to motor fluctuations and dyskinesia.
  • Invasive procedures: Deep Brain Stimulation (DBS) is effective but involves surgical risks and high costs.
  • Limited precision: Traditional approaches target specific brain regions, not broader dysfunctional networks.
  • Non-motor symptoms ignored: Cognitive decline, depression, and sleep disorders remain inadequately managed.

Advances in Brain Network Mapping

  • Shift to network-level understanding: Identifies interconnected neural circuits responsible for PD symptoms.
  • Precision targeting: Enables identification of optimal stimulation sites beyond conventional regions.
  • Personalised medicine: Tailors interventions based on individual brain connectivity patterns.

Potential of TMS

  • Non-invasive and safe: Uses magnetic fields to modulate brain activity without surgery.
  • Network modulation: Can target specific neural circuits identified through mapping.
  • Improvement in symptoms: Evidence suggests benefits in motor function, depression, and cognition.
  • Adjunct therapy: Can complement pharmacological treatments and reduce drug dependence.
  • Repeatable and scalable: Suitable for outpatient settings, improving accessibility.

Challenges and Limitations of TMS

  • Variable efficacy: Outcomes differ across patients due to heterogeneity of disease.
  • Lack of standard protocols: Optimal frequency, duration, and targets are still evolving.
  • Cost and availability: Limited access in India’s public health system.
  • Need for long-term evidence: Insufficient data on sustained benefits.

Conclusion

While existing PD treatments remain largely symptomatic, network-based approaches and TMS hold promise for more precise, non-invasive care. Scaling these innovations requires clinical validation, affordability, and integration into India’s healthcare system.